Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma

Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma

Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Taylor C. Peak, Elena M. Fenu, Michael B. Rothberg, Christopher Y. Thomas, Ronald L. Davis, Edward A. Levine
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Case Reports in Urology
Online Access:	http://dx.doi.org/10.1155/2020/8846135
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
by: Tetsuya Danno, et al.
Published: (2021-01-01)

Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01)

Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy
by: Abhishek Bhat, et al.
Published: (2019-01-01)

Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma
by: Mahdieh Fazel, et al.
Published: (2019-01-01)

Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
by: Kavita Agrawal, et al.
Published: (2019-01-01)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
by: A. A. Formozo, et al.
Published: (2021-01-01)

Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review
by: Jawaher Ansari, et al.
Published: (2018-01-01)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
by: Bartosz Chmielowski
Published: (2013-01-01)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Gérald E. Piérard, et al.
Published: (2012-01-01)

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
by: Enriqueta Felip, et al.
Published: (2024-02-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

Predictive factors for axillary pathological complete response to neoadjuvant therapy in elderly breast cancer patients
by: Yuying Wang, et al.
Published: (2025-01-01)

Neoadjuvant Radiation with Concurrent 5-FU Resulting in Complete Pathologic Response in Stage IIIB Squamous Cell Carcinoma of the Urethra
by: Krishna H. Suthar, et al.
Published: (2020-01-01)

Carcinoembryonic antigen trajectory predicts pathological complete response in advanced gastric cancer after neoadjuvant chemotherapy
by: Yonghe Chen, et al.
Published: (2025-02-01)

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
by: Paul Russo, et al.
Published: (2007-01-01)

Clinical Outcome of Patients with Complete Pathological Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancers: The Indian Scenario
by: Snita Sinukumar, et al.
Published: (2014-01-01)

Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome
by: Benjamin Chaucer, et al.
Published: (2018-01-01)

Radiomics of magnetic resonance imaging for assessment of pathological complete response to neoadjuvant therapy and long-term survival in breast cancer
by: N. V. Petrova, et al.
Published: (2023-09-01)

Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
by: Lothar Häberle, et al.
Published: (2025-01-01)

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
by: Anne Rogiers, et al.
Published: (2020-01-01)

Bilateral Asynchronous Renal Cell Carcinoma with Metastatic Involvement of the Tongue
by: Naseem Ghazali, et al.
Published: (2012-01-01)

Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers‐Based Model
by: Maria Colomba Comes, et al.
Published: (2024-12-01)

Combined morphology and radiomics of intravoxel incoherent movement as a predictive model for the pathologic complete response before neoadjuvant chemotherapy in patients with breast cancer
by: Yunyan Zheng, et al.
Published: (2025-02-01)

A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients
by: Yana Qi, et al.
Published: (2025-01-01)

Locoregional treatments of metastatic internal mammary node following neoadjuvant chemotherapy
by: Jinhui Zhang, et al.
Published: (2025-02-01)

Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemotherapy
by: Dhanya Vasudevan, et al.
Published: (2015-01-01)

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024-01-01)

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
by: Matthew Burge, et al.
Published: (2023-01-01)

CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy
by: Ashley J. Schlafstein, et al.
Published: (2018-01-01)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
by: Jaya Unnithan, et al.
Published: (2007-01-01)

Metastatic Lesion of the Tibia from Renal Cell Carcinoma
by: Piotr Młodożeniec, et al.
Published: (2021-01-01)

Engineered ipilimumab variants that bind human and mouse CTLA-4
by: Brett Robison, et al.
Published: (2025-12-01)

Metastatic Renal Cell Carcinoma to the Testis: A Clinicopathologic Analysis of Five Cases
by: Gang Wang, et al.
Published: (2020-01-01)

A Rare Subcutaneous Manifestation of Metastatic Renal Cell Carcinoma
by: Darren Yak Leong Chan, et al.
Published: (2016-01-01)

A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab
by: Behdod Poushanchi, et al.
Published: (2018-01-01)

Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab
by: Nora Chokr, et al.
Published: (2018-01-01)

Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
by: Antonio Faieta, et al.
Published: (2021-01-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)